The researchers have identified bamboo as the world’s next sustainable ‘superfood’ for global diets after conducting the first academic assessment of bamboo consumption.
The review found evidence pointing to the numerous health and nutritional benefits associated with bamboo.
Bamboo is known as the fastest growing plant on earth, with some species growing up to 90cm tall in one day. Of all countries, China and India are the largest producers of bamboo.
Bamboo could become an important superfood based on its broad nutritional profile, according to research results led by Anglia Ruskin University.
Because they are rich in protein and fiber, the shoots are naturally low in fat. It is also rich in amino acids, selenium and potassium. In addition, it is the source of several vitamins, including niacin, thiamin, vitamins A, E and B6.
The review also suggests that integrating bamboo into a regular diet could address several health concerns.
Research in humans has shown improved blood sugar control and an improved lipid profile, which may lower the risk of diabetes and improve heart health.
High levels of cellulose, hemicellulose and lignin improve digestion and promote the growth of beneficial intestinal bacteria.
Rich in anti-inflammatory and antioxidant properties, bamboo showed a reduction in cell toxicity and inflammation.
The presence of compounds in bamboo can inhibit the formation of furan and reduce the production of acrylamide, thus protecting against food contamination.
However, some researchers also raise concerns about safety risks as bamboo contains cyanogenic glycosides, which release cyanide if not neutralized.
Future prospects
Senior author Lee Smith, professor of public health at Anglia Ruskin University (ARU), said: “Bamboo is already widely eaten in parts of Asia and has huge potential to be a healthy, sustainable addition to diets around the world – but it must be prepared correctly.”
“Our review shows the clear promise of bamboo as a possible ‘superfood,’ but there are also gaps in our knowledge. We could only find four studies with human participants that met our criteria, so additional high-quality human trials are needed before we can make firm recommendations,” Smith added.
